Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=6&sort=-principal_investigator
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-principal_investigator", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1442&sort=-principal_investigator", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=7&sort=-principal_investigator", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=5&sort=-principal_investigator" }, "data": [ { "type": "Grant", "id": "16070", "attributes": { "award_id": "1R01HL179747-01A1", "title": "Adaptive-like Natural Killer cells in pulmonary cytomegalovirus reactivation", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 32514, "first_name": "EMMANUEL FRANCK", "last_name": "MONGODIN", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-07-01", "end_date": "2031-03-31", "award_amount": 795464, "principal_investigator": { "id": 44542, "first_name": "Daniel", "last_name": "Calabrese", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3484, "ror": "", "name": "UNIVERSITY OF CALIFORNIA, SAN FRANCISCO", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "AND ABSTRACT Cytomegalovirus (CMV) is a common herpesvirus that establishes latency for the lifetime of the host and drives immune dysregulation. The lung is an important reservoir for CMV in both humans and mice. CMV infection can reactivate during episodes of immunosuppression, with age, and from direct tissue injury. Importantly, CMV reactivation is associated with increased risk for death following lung transplantation, acute respiratory distress syndrome (ARDS) and SARS-CoV-2 pulmonary disease. Natural killer (NK) cells are effector innate immune cells that can recognize damaged or missing-self. They play a central role in mitigating CMV infection with long- lived tissue-resident, CMV-specific and adaptive abilities. Our prior publications have established novel roles for NK cells in mediating acute lung injury and found increased prevalence of CMV-specific NK cells in human lungs preceding injury. Our preliminary data identify tissue-resident NK cell populations as key effectors of airway- centric acute lung injury. Moreover, we found that adaptive-like NK cells are increased in tissue surrounding chronically-injured lung transplant airways. Identifying whether adaptive NK cell differentiation occurs locally in the lung in response to CMV reactivation and drives lung damage represents a fundamental gap in knowledge. Based on our observations, we hypothesize that local CMV-specific NK cell immune responses potentiate lung damage after transplant. Across 2 independent Aims we will use mouse models of CMV reactivation and observations in 2 established human lung transplant cohorts to investigate mechanisms of adaptive NK cell lung injury. Aim 1 will determine the impact of CMV reactivation on the adaptive NK cell response in the mouse and human lung. We will use 2 lung transplant mouse models and a previously recruited cohort of 56 lung transplant recipients’ bronchoalveolar lavage and tissue samples to measure NK cell phenotypes and spatial distributions relative to CMV activity and to probe the mechanism whereby lung adaptive NK cells develop in the allograft. In a non-interdependent fashion, Aim 2 will determine the mechanisms through which adaptive NK cells potentiate acute injury and their role in establishing allograft tolerance using established orthotopic allogeneic mouse lung transplant models. These proposed innovative approaches will examine the novel concept that tissue injury potentiates geographic residency of CMV-specific adaptive NK cell populations, raising the allograft immune tone and the risk for lung allograft damage. Work resulting from this proposal will be broadly applicable to other solid organ transplant recipients and patients suffering from acute respiratory distress syndrome and acute exacerbations of chronic lung disease. Importantly, we will identify: mechanisms of novel biology, cell populations that may risk stratify clinical outcomes, and new rational targets for future prevention and treatment of lung allograft syndromes.", "keywords": [ "Acute", "Acute Lung Injury", "Acute Respiratory Distress Syndrome", "Adaptive Immune System", "Adoptive Transfer", "Age", "Allogenic", "Allograft Tolerance", "Allografting", "Anti-viral Therapy", "Antigen-Presenting Cells", "B-Lymphocytes", "Biological Markers", "Biology", "Biopsy", "Bronchoalveolar Lavage", "COVID-19/ARDS", "Cell Compartmentation", "Cell Differentiation process", "Cells", "Cessation of life", "Chronic", "Chronic Lung Injury", "Chronic lung disease", "Clinical stratification", "Collaborations", "Complement", "Contracts", "Cytomegalovirus", "Cytomegalovirus Infections", "Data", "Development", "Effector Cell", "Flow Cytometry", "Functional disorder", "Funding", "Future", "Geography", "Graft Tolerance", "Herpesviridae", "Herpesviridae Infections", "Human", "Immune", "Immune response", "Immunity", "Immunosuppression", "Injury", "Innate Immune System", "Interleukin-15", "Knowledge", "Laboratories", "Lung", "Lung Diseases", "Lung Transplantation", "Lung infections", "Measures", "Mediating", "Memory", "Modality", "Morbidity", "Murid herpesvirus 1", "Mus", "Natural Killer Cells", "Organ Transplantation", "Outcome", "Pathology", "Patient Care", "Phenotype", "Play", "Population", "Prevalence", "Prevention", "Publications", "Reperfusion Injury", "Research", "Residencies", "Risk", "Risk Factors", "Role", "Sampling", "Solid", "Spatial Distribution", "Specificity", "Structure of parenchyma of lung", "Surgical Models", "Syndrome", "T-Lymphocyte", "Time", "Tissue Sample", "Tissues", "Transplant Recipients", "Transplantation", "United States National Institutes of Health", "Viral", "Virus", "Virus Diseases", "Work", "allograft rejection", "cell killing", "cohort", "cytokine", "cytomegalovirus receptor", "graft dysfunction", "innovation", "insight", "lung allograft", "lung injury", "lung ischemia", "mortality", "mortality risk", "mouse genetics", "mouse model", "novel", "novel diagnostics", "novel therapeutics", "organ transplant recipient", "pulmonary", "receptor", "recruit", "response", "risk stratification", "seropositive", "spatial transcriptomics", "stem", "success", "therapeutic target", "tissue injury", "transplant model" ], "approved": true } }, { "type": "Grant", "id": "16069", "attributes": { "award_id": "1R01HL178722-01A1", "title": "Control of virus-induced lung sequelae by P2RX7-expressing CD4+ T cells", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 44231, "first_name": "INGRID CECILIA", "last_name": "ESPINOZA GRANDON", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-07-15", "end_date": "2028-06-30", "award_amount": 1665204, "principal_investigator": { "id": 44541, "first_name": "Henrique", "last_name": "Borges da Silva", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 20818, "first_name": "Jie", "last_name": "Sun", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1426, "ror": "", "name": "MAYO CLINIC ROCHESTER", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true } ] } ], "awardee_organization": { "id": 3483, "ror": "", "name": "MAYO CLINIC ARIZONA", "address": "", "city": "", "state": "AZ", "zip": "", "country": "United States", "approved": true }, "abstract": "Project summary: The overarching goal of this project is to define how the damage induced by severe respiratory infections can promote pathogenic lung CD4+ T cells which, in turn, perpetuates the lung sequelae. In response to infections such as influenza or SARS-CoV2, T cells are recruited to the lung parenchyma and establish tissue residency. That includes helper CD4+ T cells, which produce cytokines and support other lung immune responses. In mild infected individuals, lung-resident CD4+ T cells can form protective memory populations, which are important against viral re-exposure. In contrast, severe infections with these viruses can lead to an excessive accumulation of lung-resident CD4+ T cells, which is correlated with the development of widespread lung damage, which is often not reversible. These non-reversible sequelae are typical clinical observations of patients with “Long COVID” and (more recently appreciated) “Long Flu”, i.e., patients with irreversible loss of organ function due to past respiratory viral infections. Understanding how and whether lung pathogenic CD4+ T cell responses form will pave the way for novel strategies to prevent or treat the long-term complications of respiratory viral infections. On this direction, we found, in recently published studies, that lung- resident CD4+ T cells with characteristics of the follicular helper subset (called “tissue-resident helper” or TRH cells) accumulate at excessive numbers in response to severe influenza-infected mice and in COVID-19 patients with lung sequelae. These lung TRH cells express high levels of the receptor P2RX7, a purinergic ion channel that responds to the “danger signal” extracellular ATP (eATP). Notably, our recently published studies also defined that expression of P2RX7 is necessary for the accumulation of lung TRH cells in response to severe influenza, and knockout of this molecule protects mice from long-term lung damage. In this proposal, we aim to define how recognition of eATP through P2RX7 promotes the establishment of pathogenic lung TRH cells, and if P2RX7 blockade can prevent or revert lung sequelae caused by severe respiratory infections. In Aim 1, we will determine how P2RX7/eATP promotes the ability of CD4+ T cells to enter the lung tissue and differentiate into pathogenic TRH cells. We will build upon preliminary data and test the hypothesis that P2RX7 is needed for (a) the induction of CXCR3-mediated CD4+ T cell lung parenchymal infiltration, and (b) their localization into lung dysplastic areas for the conversion into the TRH cell phenotype. To answer these questions, we will use a combination of genetic and pharmacological approaches, as well as a series of ex vivo and in vivo imaging and spatial transcriptomics assessments. In Aim 2, we will test if pharmacological inhibition of P2RX7 can be used to (a) prevent and/or (b) revert the lung sequelae caused by severe influenza or SARS-CoV2. We will build upon preliminary data showing that blockade of this receptor is sufficient to decrease the numbers of lung TRH cells. Our proposed studies will define how eATP regulate lung-resident pathogenic CD4+ T cell responses, and how P2RX7 blockade can be used therapeutically to treat lung disease caused by respiratory viruses.", "keywords": [ "2019-nCoV", "ATP Receptors", "Affect", "Area", "CD4 Positive T Lymphocytes", "COVID-19", "COVID-19 patient", "CXCR3 gene", "Cell Count", "Cell Death", "Cells", "Cessation of life", "Characteristics", "Chemotaxis", "Chronic", "Clinical", "Communication", "Data", "Development", "Disease", "Elderly", "Functional disorder", "Future", "Genetic", "Goals", "Immune", "Immune response", "Immunity", "Immunofluorescence Immunologic", "Individual", "Infection", "Infiltration", "Inflammation", "Influenza", "Ion Channel", "Knock-out", "Knockout Mice", "Knowledge", "Long COVID", "Lung", "Lung Diseases", "Lung immune response", "Lung infections", "Mediating", "Memory", "Molecular", "Morbidity", "Mus", "Organ", "Pathogenesis", "Pathogenicity", "Pathology", "Patient Observation", "Patients", "Pattern", "Persons", "Phenotype", "Pneumonia", "Population", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Primary Infection", "Probability", "Public Health", "Publishing", "Pulmonary Pathology", "Residencies", "Resolution", "Respiratory Tract Infections", "Series", "Severity of illness", "Signal Transduction", "Structure of parenchyma of lung", "T cell response", "T-Lymphocyte", "Testing", "Therapeutic Uses", "Tissues", "Upregulation", "Viral", "Viral Pneumonia", "Viral Respiratory Tract Infection", "Virus", "aging population", "chronic complications", "cytokine", "ex vivo", "extracellular", "flu", "folate-binding protein", "handicapping condition", "immunoregulation", "improved", "in vivo imaging", "influenza infection", "loss of function", "lung health", "lung injury", "novel strategies", "old mice", "overexpression", "pharmacologic", "prevent", "pulmonary function", "receptor", "recruit", "respiratory virus", "response", "spatial transcriptomics" ], "approved": true } }, { "type": "Grant", "id": "16068", "attributes": { "award_id": "1F31AI200222-01", "title": "Biogenesis and function of astrovirus replication organelles", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 44307, "first_name": "RODOLFO M", "last_name": "ALARCON", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-07-01", "end_date": "2028-10-31", "award_amount": 44209, "principal_investigator": { "id": 44540, "first_name": "Brooke McKayla", "last_name": "Bengert", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3482, "ror": "", "name": "UNIVERSITY OF ALABAMA AT BIRMINGHAM", "address": "", "city": "", "state": "AL", "zip": "", "country": "United States", "approved": true }, "abstract": "Human astroviruses (HAstV) are positive sense, single-stranded RNA (+ssRNA) viruses and an understudied, globally prevalent cause of non-bacterial gastroenteritis. The recent isolation of novel HAstVs from children with severe or fatal infections of the nervous system revealed close phylogenetic clustering with animal-restricted viruses, highlighting a potential for zoonosis and an urgent, unmet need for effective treatments. However, gaps in knowledge for the basic biology of astrovirus replication and pathogenesis complicate the design of targeted antiviral interventions. An essential step for all productive +ssRNA virus infections is the manipulation of intracellular membranes to construct replication organelles (RO), or specialized compartments that concentrate factors for viral replication. Using immunofluorescence (IF) and transmission electron microscopy (TEM), we identified that the activities of both endoplasmic reticulum (ER)-anchored HAstV nonstructural proteins, nsp1a/1 and nsp1a/2, facilitate the remodeling of ER membrane into networks of double membrane vesicles (DMV) that isolate replicating RNA from the cytoplasm. However, the mechanisms that direct RO formation and the process by which replicated RNA reaches the cytoplasmic compartment for virion packaging remain elusive. Thus, this proposal seeks to understand the structural and molecular determinants of astrovirus RO formation and function by characterizing the independent and mutual interactions of nsp1a/1 and nsp1a/2. Aim 1 will test the hypothesis that dimerization enabled by a well-conserved leucine zipper motif drives nsp1a/1-mediated ER remodeling. This will be addressed using microscopy, biochemical assays, and reverse genetics approaches to probe the influence of dimerization on nsp1a/1-mediated ER remodeling and viral fitness. In Aim 2, we will test the hypothesis that nsp1a/2 performs a similar role to the coronavirus nsp4, forming an oligomer capable of inducing membrane curvature and assembling a DMV pore complex involved in RNA transport. Using cryo-FIB-SEM and electron tomography, we will elucidate the structure of nsp1a/2 in situ to reveal residues essential for oligomerization and interactions with viral RNA. The importance of these residues in nsp1a/2-mediated ER remodeling and viral fitness will be validated by site-directed mutagenesis, reverse genetics, and microscopy. In Aim 3, we will test the hypothesis that nsp1a/1 and nsp1a/2 interact to coordinate RO biogenesis. The domains of interaction will be mapped by co-immunoprecipitation and truncation of each viral protein in a co-expression system, and the influence of this interaction on productive DMV biogenesis will be assessed by IF and TEM. The indispensable role of ROs in the replication and assembly of +ssRNA viral progeny establishes the interactions of nsp1a/1 and nsp1a/2 as attractive, potentially druggable targets for effective therapeutics. Thus, understanding the specific domains and residues required for nsp1a/1- and nsp1a/2-mediated RO biogenesis will aid in the rational design of antivirals targeting this essential step of astrovirus infection.", "keywords": [ "Acute", "Address", "Amino Acid Sequence", "Animals", "Anti-viral Agents", "Astrovirus", "Biochemical", "Biogenesis", "Biological Assay", "Biology", "Bulla", "Central Nervous System Infections", "Child", "Co-Immunoprecipitations", "Complex", "Coronavirus", "Cytoplasm", "Data", "Development", "Dimerization", "Disease", "Disparate", "Elderly", "Endoplasmic Reticulum", "Gastroenteritis", "Goals", "Homo", "Homodimerization", "Human", "Immunocompromised Host", "Immunofluorescence Immunologic", "Immunofluorescence Microscopy", "In Situ", "Individual", "Infection", "Intervention", "Intracellular Membranes", "Knowledge", "Leucine Zippers", "Link", "Maps", "Mediating", "Membrane", "Microscopy", "Modeling", "Molecular", "Nonstructural Protein", "Organelles", "Pathogenesis", "Phylogenetic Analysis", "Plasmids", "Polyproteins", "Process", "Production", "Productivity", "Proteins", "RNA", "RNA Transport", "RNA chemical synthesis", "RNA replication", "Research", "Research Training", "Role", "Site-Directed Mutagenesis", "Source", "Stains", "Structure", "System", "Testing", "Transmembrane Domain", "Transmission Electron Microscopy", "Vaccines", "Vesicle", "Viral", "Viral Nonstructural Proteins", "Viral Packaging", "Viral Proteins", "Virion", "Virus", "Virus Assembly", "Virus Diseases", "Virus Replication", "antiviral drug development", "combat", "design", "druggable target", "effective therapy", "electron tomography", "gastrointestinal", "genetic approach", "insight", "live cell imaging", "nervous system infection", "novel", "particle", "pathogen", "protein function", "rational design", "reverse genetics", "structural biology", "structural determinants", "synergism", "therapeutically effective", "training project", "viral RNA", "viral fitness" ], "approved": true } }, { "type": "Grant", "id": "16067", "attributes": { "award_id": "1R43AI191918-01A1", "title": "A single-domain antibody-based lateral flow assay for Tuberculosis", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32562, "first_name": "KAREN A", "last_name": "LACOURCIERE", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-07-01", "end_date": "2028-06-30", "award_amount": 300000, "principal_investigator": { "id": 44539, "first_name": "Timothy Andrew", "last_name": "Bates", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3481, "ror": "", "name": "ALPACURE LLC", "address": "", "city": "", "state": "OR", "zip": "", "country": "United States", "approved": true }, "abstract": "Despite significant efforts over the past century, tuberculosis (TB) remains a formidable global health challenge. Mycobacterium tuberculosis (Mtb), the causative agent of TB, infects approximately 2 billion people worldwide. According to the WHO, the incidence of TB began rising for the first time in decades in 2021, in 2022 there were an estimated 10.6 million new cases, and 1.3 million lives lost. Despite these alarming numbers, a significant gap in the fight against TB remains due to the lack of effective diagnostic measures. As many as 30% of estimated cases go undiagnosed, a severe oversight that fuels community transmission and hinders disease control efforts. The situation is further exacerbated by the emergence of multidrug resistant strains, making prompt and accurate diagnosis increasingly vital. To address this unmet medical need, we propose the development of a low-cost, low-complexity TB lateral flow assay (LFA)-based diagnostic test, offering convenience comparable to the COVID-19 at-home rapid antigen tests. Our innovative approach centers on the use of variable heavy chain antibody fragments (VHH), also known as single-domain antibodies. These antibody fragments are just one-tenth the size of conventional antibodies and possess several advantageous features including high thermostability and low production costs. They can also achieve higher binding site density due to the removal of FC domains, improving their potential sensitivity. These characteristics make VHHs particularly well-suited for low-cost point-of-care diagnostics. We intend to focus on the detection of Mtb derived antigens shown to have strong performances in more complex and more expensive diagnostic approaches. In this Phase I application, we propose to refine a VHH optimization platform, leveraging our established phage-display discovery process and our existing VHH candidates, and we will also produce and test bivalent VHH constructs using a rapid screening method. We will then produce two LFA prototypes (visual read and fluorescent), and test them using real-world TB samples to determine the sensitivity and specificity of our test. Upon completion of this study, we expect to have prototype LFAs utilizing well-characterized VHH candidates capable of effectively detecting TB antigens in clinical TB samples. This foundational work will forward development of a test for rapid and efficient TB case finding in low-resource settings, addressing a major gap in accessible, cost-effective TB diagnostics. We hope to bring this vital technology to regions bearing a high burden of the disease, thereby contributing significantly to the global effort to eradicate TB.", "keywords": [ "Address", "Affinity", "Africa South of the Sahara", "Antibodies", "Antigens", "Area", "Bacteriophages", "Binding", "Binding Sites", "Biological Assay", "Biological Markers", "Blood", "COVID-19", "Cause of Death", "Characteristics", "Chemicals", "Clinical", "Collaborations", "Communicable Diseases", "Complex", "Country", "Detection", "Development", "Diagnosis", "Diagnostic", "Diagnostic tests", "Directed Molecular Evolution", "Drug resistance", "Drug resistance in tuberculosis", "Engineering", "Ensure", "Enzyme-Linked Immunosorbent Assay", "Epidemic", "Equipment", "Excision", "Fc domain", "Fluorescence", "Future", "HIV Seronegativity", "HIV Seropositivity", "HIV/TB", "Health", "Home", "Immunoglobulin Fragments", "Incidence", "Interferometry", "Left", "Light", "Mass Spectrum Analysis", "Measures", "Medical", "Membrane", "Methods", "Multi-Drug Resistance", "Mycobacterium tuberculosis", "Mycobacterium tuberculosis antigens", "Patients", "Performance", "Persons", "Phage Display", "Phase", "Price", "Process", "Production", "Pulmonary Tuberculosis", "Rapid screening", "Reader", "Reagent", "Reporting", "Resource-limited setting", "Resources", "Sampling", "Selection Criteria", "Sensitivity and Specificity", "Small Business Innovation Research Grant", "Southeastern Asia", "Specialist", "Specificity", "Structure", "Technology", "Testing", "Time", "Training", "Tuberculosis", "Tuberculosis diagnosis", "Update", "Validation", "Visual", "Work", "accurate diagnosis", "antigen binding", "antigen detection", "antigen test", "burden of illness", "case finding", "chemical stability", "clinically relevant", "co-infection", "commercialization", "community transmission", "cost", "cost effective", "cost estimate", "demographics", "density", "design", "diagnostic strategy", "disorder control", "experience", "fighting", "global health", "improved", "innovation", "lateral flow assay", "manufacture", "nanoGold", "nanobodies", "next generation", "point of care testing", "point-of-care diagnostics", "prevent", "preventable death", "prototype", "rapid test", "resistant strain", "scale up", "screening", "success", "test strip", "thermostability", "tuberculosis diagnostics" ], "approved": true } }, { "type": "Grant", "id": "16066", "attributes": { "award_id": "1R21AI196701-01A1", "title": "Signal transduction mechanisms used by a group of uncharacterized ITAM- containing receptors in jawless vertebrates", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 44537, "first_name": "YAN", "last_name": "WANG", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-07-01", "end_date": "2028-06-30", "award_amount": 233444, "principal_investigator": { "id": 44538, "first_name": "Byron Benton", "last_name": "Au-Yeung", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3480, "ror": "", "name": "EMORY UNIVERSITY", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "Chimeric antigen receptors (CARs) are form of precision immunotherapy approved for the treatment of hematologic malignancies. Nearly all CARs invariantly incorporate the same Immunoreceptor tyrosine-based activation motifs (ITAMs) from human CD3 ZETA to stimulate the primary activation signal pathway in immune cells (aka “Signal 1”). However, a one-size-fits-all approach likely does not trigger optimal Signal 1 activation across different CAR applications/conditions. For example, excessive Signal 1 activation can result in toxicity by “cytokine storm”, or CAR-T cell exhaustion. We propose that sequence-divergent ITAMs could activate cells with varying kinetics or intensities, which would be beneficial for customizing CAR-based immunotherapy. In this project, we investigate novel ITAMs sourced from the most distantly related species to humans that are thought to utilize the ITAM mechanism in their immune systems: the Sea lamprey. Lampreys are jawless vertebrates that feature an alternative form of adaptive immunity. In preliminary studies, we identified novel lamprey ITAMs, some of which exhibit amino acid sequence differences that differ from the mammalian ITAM consensus sequence. We hypothesize that these divergent ITAMs in CARs could activate cellular functions with varying strengths. The significance of this unexplored field is that this work has the potential to reveal novel ITAMs that are beneficial for immunotherapy and also to gain fundamental insights into the origins of adaptive immunity. In Specific Aim 1, we will identify which of the previously uncharacterized ITAMs can activate a human T cell. We will test this hypothesis with innovative “Mermaid” CARs, which consist of the extracellular and transmembrane domains of human origin, fused to the cytoplasmic tails of lamprey ITAM-containing receptors. We will analyze the capacity of these novel CARs to stimulate activating signals first in the Jurkat human T cell line, then in primary human T cells. Preliminary studies indicate that this approach is feasible. The goal of Specific Aim 2 is to identify the proteins that associate with ITAM containing receptors in primary lamprey peripheral blood leukocytes. We will use the SH2 domains of SYK family kinases to pull-down lamprey ITAM containing receptors and identify these proteins by mass spectrometry. This work will confirm the binding specificity of these divergent ITAM domains. Impact: At the conclusion of these studies, we will know which of the novel lamprey ITAMs can function in a human T cell system. The knowledge gained from this work will expand the “toolbox” of potential ITAMs that can be used to modulate the intensity or kinetics of CAR signaling. This work will also open a new area of immune receptor biology by identifying the receptors that utilize ITAMs in the jawless vertebrate adaptive immune system. This work will provide new insights into how the mechanisms used by our immune receptors may have originated. Furthermore, this work will show that signaling mechanisms from divergent sources could be useful for engineering novel therapeutic immune receptors.", "keywords": [ "Adaptive Immune System", "Adoption", "Amino Acid Motifs", "Amino Acid Sequence", "Antigen Receptors", "Area", "Autologous", "B-Cell Antigen Receptor", "Binding", "Biology", "CAR T cell therapy", "CD19 gene", "CD3 Antigens", "CD94 Antigen", "Cell Line", "Cell Physiology", "Cells", "Chimeric Proteins", "Chronic", "Clinical", "Collaborations", "Consensus Sequence", "Cytoplasmic Tail", "Distant", "Engineering", "Exhibits", "Family", "Fc Receptor", "Gene Expression Profiling", "Goals", "Hematologic Neoplasms", "Human", "ITAM", "Immune", "Immune system", "Immunologic Receptors", "Immunotherapy", "In Vitro", "Inflammatory", "Kinetics", "Knowledge", "Lampreys", "Leukocytes", "Mammals", "Mass Spectrum Analysis", "Pathway interactions", "Petromyzon marinus", "Phenotype", "Phosphorylation", "Phosphotransferases", "Production", "Proteins", "Proteomics", "Receptor Signaling", "Research Personnel", "Resources", "SYK gene", "Series", "Signal Induction", "Signal Pathway", "Signal Transduction", "Signal Transduction Pathway", "Signaling Protein", "Source", "Specificity", "Stimulus", "System", "T cell response", "T-Cell Activation", "T-Cell Receptor", "T-Lymphocyte", "TNF gene", "Testing", "Time", "Toxic effect", "Transmembrane Domain", "Tumor Antigens", "Tyrosine Phosphorylation", "Vertebrates", "Work", "ZAP-70 Gene", "adaptive immunity", "chimeric antigen receptor", "chimeric antigen receptor T cells", "cytokine", "cytokine release syndrome", "design", "exhaustion", "extracellular", "innovation", "insight", "novel", "novel therapeutics", "peripheral blood", "personalized immunotherapy", "protein protein interaction", "receptor", "recruit", "release of sequestered calcium ion into cytoplasm", "response", "src Homology Region 2 Domain" ], "approved": true } }, { "type": "Grant", "id": "16065", "attributes": { "award_id": "1R21AI193667-01A1", "title": "Determining the role of the cytokine interleukin-22 (IL-22) in SARS-CoV-2 infection", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 44528, "first_name": "AARON MICHAEL", "last_name": "JOFFE", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-08-10", "end_date": "2028-07-31", "award_amount": 178750, "principal_investigator": { "id": 44536, "first_name": "Lauren A", "last_name": "Zenewicz", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3479, "ror": "", "name": "UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR", "address": "", "city": "", "state": "OK", "zip": "", "country": "United States", "approved": true }, "abstract": "SARS-CoV-2 infection often has lasting, long-term effects on people’s health. Post-acute sequelae SARS-CoV- 2 infection (PASC), informally called “Long COVID”, is a clinically heterogenous disease with different patients having different affected tissues. In addition to the lungs, the site of primary infection, PASC patients also report issues with other tissues, including the gastrointestinal (GI) tract. Although we still do not understand the mechanisms for PASC, there is an urgent need to identify therapeutics to prevent and/or treat PASC patients. Early in the pandemic, COVID-19 patients were described as having a cytokine storm that is likely one of the major complications leading to PASC. Although many of these cytokines contribute to tissue damage and destruction, interleukin-22 (IL-22) is well-described to be protective to inflamed tissues in diseases such as airway inflammation and inflammatory bowel disease. IL-22 stimulation alters the transcriptional profile of epithelial cells within the target tissues to increase cellular proliferation and decrease sensitivity to apoptosis. IL- 22 can also aid in wound repair and recombinant IL-22-Fc is in clinical trials for the treatment of flares in ulcerative colitis patients and tissue repair in patients with acute graft versus host disease. There is a gap in our knowledge of how individual cytokines may affect patient outcomes and if they can be used for preventing or repairing tissue damage. Our hypothesis is that IL-22 is a protective cytokine to tissues during SARS-CoV-2 infection. In this proposal we will examine the role of IL-22 in vitro in respiratory and GI cells and in an in vivo mouse model of SARS-CoV-2 infection. Our overall objective is to determine if IL-22 is a protective cytokine in this disease and can be beneficial to the lung and GI tissues during infection. Upon completion of these aims, the expected outcome is a new understanding of the critical role of the cytokine IL-22 in SARS-CoV-2 infection. This breakthrough will have a positive impact on our understanding of immune responses to SARS-CoV-2 infection as they may provide strong evidence-based rationale for further development of IL-22 biology targeted therapies in the prevention and/or treatment of PASC.", "keywords": [ "2019-nCoV", "Acute Graft Versus Host Disease", "Affect", "Anti-viral Response", "Apoptosis", "Biology", "COVID-19 patient", "COVID-19 susceptibility", "Cell Line", "Cell Proliferation", "Cells", "Clinical", "Clinical Treatment", "Clinical Trials", "Colon", "Data", "Development", "Disease", "Disease Progression", "Down-Regulation", "Epithelial Cells", "Flare", "Gastrointestinal tract structure", "Gene Expression Profile", "Genes", "Genetic Transcription", "Goals", "Health", "Human", "Immune response", "Immunology", "In Vitro", "Individual", "Infection", "Inflammation", "Inflammatory Bowel Diseases", "Inhibition of Apoptosis", "Knowledge", "Laboratories", "Long COVID", "Long-Term Effects", "Lung", "Mission", "Monitor", "Morbidity", "Mus", "Organoids", "Outcome", "Pathology", "Patient-Focused Outcomes", "Patients", "Persons", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Predisposition", "Prevention", "Primary Infection", "Proliferating", "Public Health", "Recombinant Interleukins", "Reporting", "Research", "Role", "SARS-CoV-2 infection", "STAT3 gene", "Series", "Serum", "Signal Transduction", "Site", "Technology", "Therapeutic", "Tissues", "Transcriptional Regulation", "Ulcerative Colitis", "United States", "United States National Institutes of Health", "Upregulation", "Viral", "Viral Load result", "Virus", "Virus Diseases", "Wild Type Mouse", "airway inflammation", "chemokine", "cytokine", "cytokine release syndrome", "evidence base", "experimental study", "gastrointestinal", "human disease", "in vivo", "in vivo Model", "insight", "interleukin-22", "mouse model", "nanostring", "pandemic disease", "pathogen", "prevent", "receptor", "respiratory", "targeted treatment", "tissue repair", "wound healing" ], "approved": true } }, { "type": "Grant", "id": "16064", "attributes": { "award_id": "1R21AI202433-01", "title": "Novel In-Clinic Molecular Adjuvant Enhances Antiviral Humoral Immunity of Vaccines Across Sexes", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 44528, "first_name": "AARON MICHAEL", "last_name": "JOFFE", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-08-07", "end_date": "2028-07-31", "award_amount": 234370, "principal_investigator": { "id": 44535, "first_name": "ZHAOYANG", "last_name": "YOU", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3478, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Novel In-Clinic Molecular Adjuvant Enhances Antiviral Humoral Immunity of Vaccines Across Sexes Abstract Females typically generate more effective humoral immunity of vaccines (e.g., influenza vaccine) than males. Discovering safe and effective adjuvants, which are crucial for vaccinations, to enhance immunogenicity of viral antigens across sexes is an urgent need. We have found the in-clinic small molecule latanoprost that promotes intradermally co-delivered influenza H1N1 Hemagglutinin (HA) or SARS-CoV-2 Spike (S) protein vaccine for inducing HA-specific IgG1 or S-specific neutralizing antibody (NAb) across sexes in C57BL/6 mice. HA or S protein vaccine alone induces a remarkable difference of IgG1 or NAb responses in females vs. males; interestingly, latanoprost preferentially promotes IgG1 or NAb responses to HA or S protein vaccine in males, resulting in a reduced difference to a comparable level of IgG1 or NAb in males vs. females. Conventional type 1 DC (cDC1) are tied to long-lasting NAb responses following latanoprost-adjuvanted vaccinations. There are more migratory cDC1 in the skin of females than males; intriguingly, latanoprost increases skin migratory cDC1 across sexes, with a greater effectiveness in males, leading to a similar level of migratory cDC1 in the skin of females vs. males. Combined data from both females and males demonstrate that latanoprost-adjuvanted vaccines are superior to non-adjuvanted vaccines in eliciting humoral responses to viral antigens. We hypothesize that latanoprost increases migratory cDC1 and eliminates their differences between females and males in the skin to enhance antiviral humoral immunity of vaccines across sexes. We will 1) explore the mechanisms by which latanoprost enhances humoral responses to viral antigens in males and females, and 2) develop latanoprost-adjuvanted vaccines across sexes. If successful, we will discover latanoprost as a novel in-clinic molecular adjuvant to enhance humoral responses to viral antigens in males and females and develop clinically translatable latanoprost-adjuvanted influenza and SARS-CoV-2 vaccines across sexes which differ from past reports for female-biased humoral responses to conventional vaccines.", "keywords": [ "Adjuvant", "Adjuvanticity", "Agonist", "Androgens", "Antibody Response", "Antigens", "B-Lymphocytes", "Blood", "C57BL/6 Mouse", "COVID-19 vaccine", "Chronic", "Clinic", "Data", "Disproportionately impacts women", "Effectiveness", "FLT3 ligand", "Female", "Flow Cytometry", "Formulation", "Gene Expression Profile", "Helper-Inducer T-Lymphocyte", "Hemagglutinin", "Hormonal", "Hormones", "Humoral Immunities", "IgG1", "Immunoglobulin G", "Inbred BALB C Mice", "Inbreeding", "Inflammatory Response", "Influenza", "Influenza A Virus H1N1 Subtype", "Latanoprost", "Link", "Mediating", "Molecular", "Mus", "PGF receptor", "Pfizer-BioNTech COVID-19 vaccine", "Pharmaceutical Preparations", "Prostaglandins", "Protein Analysis", "Proteins", "Reporting", "Role", "SARS-CoV-2 spike protein", "Sex Bias", "Skin", "Structure of germinal center of lymph node", "Swiss Mice", "TLR7 gene", "Testing", "Vaccination", "Vaccines", "Viral", "Viral Antigens", "Virus", "XCR1 gene", "antagonist", "antiviral immunity", "clinical translation", "cytokine", "cytokine release syndrome", "draining lymph node", "immunogenicity", "improved", "influenza virus vaccine", "influenzavirus", "irritation", "male", "migration", "neutralizing antibody", "novel", "old age", "preclinical development", "protein expression", "receptor", "response", "sex", "single-cell RNA sequencing", "small molecule", "vaccine development", "vaccine immunogenicity", "women versus men" ], "approved": true } }, { "type": "Grant", "id": "16062", "attributes": { "award_id": "1K99AI201799-01", "title": "Formation and restriction of coronavirus double-membrane vesicles", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32891, "first_name": "MARY KATHERINE BRADFORD", "last_name": "PLIMACK", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-08-01", "end_date": "2028-07-31", "award_amount": 174640, "principal_investigator": { "id": 44534, "first_name": "Michael Armen", "last_name": "Tartell", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3476, "ror": "", "name": "ROCKEFELLER UNIVERSITY", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Coronaviruses induce the formation of double-membrane vesicles (DMVs) derived from the endoplasmic reticulum (ER), highly conserved structures in positive-sense RNA viruses which serve as the hub for viral RNA synthesis. Yet a detailed mechanistic understanding of their formation, innate immune processes which target them, and whether viruses have evolved to evade such targeting is unknown. During my postdoctoral training, I have identified and validated ring finger protein 213 (RNF213) as an interferon-gamma induced gene (ISG) which restricts the human coronavirus OC43. I developed novel reporter viruses to define the role of RNF213 in infection and discovered that it inhibits primary translation, but not entry, of OC43. RNF213 co-localized with and co-immunoprecipitated OC43 nonstructural protein 3 (NSP3), the main structural component of the coronavirus DMV. However, RNF213 had no impact on SARS-CoV-2 and did not localize to SARS-CoV-2 DMVs. My work has identified not only an ISG that restricts coronavirus DMVs, but also raises new questions about differences between DMV formation in coronaviruses. In the mentored phase of this K99 Pathway to Independence award, I will obtain a complete mechanistic understanding of the restriction of coronaviruses by RNF213. In Aim 1, I will define how RNF213 binds directly or indirectly to OC43 NSP3, the domains required, and how SARS-CoV-2 evades restriction. In Aim 2, I will define cellular co-factors required for the localization and activity of RNF213 against OC43, including which of the domains of RNF213 are required for restriction. I will also determine the role of cellular RNF213-interacting proteins I have recently identified. Achieving these aims will train me in virology, molecular biology, and microscopy methods to study coronavirus DMVs. This will prepare me for Aim 3, in which I will define the requirements for DMVs formation in positive-sense RNA viruses. I will determine how viral proteins are inserted into the ER to form DMVs, what cellular co-factors are required for the process of DMV formation, and whether these mechanisms vary between different coronaviruses. In addition to building my scientific knowledge, my training plan will provide me with the tools necessary to advance my career development and navigate the transition to independence. The training phase will take place in the laboratory of Dr. Paul Bieniasz at The Rockefeller University, one of the world’s experts in studying how ISGs restrict viruses. I will execute a comprehensive training plan cementing not only my scientific skills, but also workshops and seminars on laboratory management, conducting a job search, research ethics, and completing the transition to independence. I will benefit from a high knowledgeable advisory committee, including Drs. Charles Rice, Seth Darst, and Elizabeth Campbell, who will both provide essential scientific feedback and career advice. The training provided by this award will be essential to achieving my goal to become an independent investigator, and the completion of this work will provide novel and significant insights into the mechanisms of DMV formation, and antiviral mechanisms to restrict them.", "keywords": [ "2019-nCoV", "ATP phosphohydrolase", "Advisory Committees", "Award", "Bacteria", "Binding", "Biochemical", "CRISPR screen", "Cells", "Cementation", "Co-Immunoprecipitations", "Coronavirus", "Coronavirus Infections", "Cytoplasm", "DNA Viruses", "Data", "Development", "Educational workshop", "Endoplasmic Reticulum", "Environment", "Feedback", "Genes", "Genetic", "Goals", "Human", "Immune", "Individual", "Infection", "Interferon Type II", "Interferons", "Knowledge", "Laboratories", "Life Cycle Stages", "Lipid Binding", "Lipids", "Lipopolysaccharides", "Membrane", "Mentors", "Methods", "Microscopy", "Molecular Biology", "Nonstructural Protein", "Occupations", "Parasites", "Pathogenicity", "Pathway interactions", "Phase", "Polyproteins", "Process", "Proteins", "RNA Viruses", "RNA chemical synthesis", "Reporter", "Research Ethics", "Research Personnel", "Rice", "Ring Finger Domain", "Role", "Salmonella typhimurium", "Structure", "System", "Techniques", "Toxoplasma gondii", "Training", "Translations", "Universities", "Vacuole", "Vesicle", "Viral", "Viral Genome", "Viral Proteins", "Virus", "Virus Diseases", "Virus Replication", "Work", "betacoronavirus", "career", "career development", "cofactor", "domain mapping", "human coronavirus", "insight", "novel", "novel strategies", "novel therapeutic intervention", "obligate intracellular parasite", "overexpression", "pathogen", "post-doctoral training", "reverse genetics", "skills", "tool", "ubiquitin ligase", "viral RNA", "virology" ], "approved": true } }, { "type": "Grant", "id": "16061", "attributes": { "award_id": "1R01HL182700-01A1", "title": "Immune determinants of lung sequelae post-acute viral infection", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 44231, "first_name": "INGRID CECILIA", "last_name": "ESPINOZA GRANDON", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-08-24", "end_date": "2029-05-31", "award_amount": 354982, "principal_investigator": { "id": 44533, "first_name": "In Su", "last_name": "Cheon", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 20818, "first_name": "Jie", "last_name": "Sun", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1426, "ror": "", "name": "MAYO CLINIC ROCHESTER", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true } ] } ], "awardee_organization": { "id": 3475, "ror": "", "name": "UNIVERSITY OF VIRGINIA", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true }, "abstract": "Severe respiratory viral infections can cause long-lasting lung damage, leading to persistent dyspnea, compromised lung function, and non-resolving fibrosis. The COVID-19 pandemic highlights these issues, with over 60 million individuals experiencing post-acute sequelae of SARS-CoV-2 (PASC). Our preliminary studies indicate that an aberrant immune-epithelial niche drives post-viral lung fibrosis, distinct from idiopathic pulmonary fibrosis. Chronic activation of virus-specific or autoreactive CD8⁺ T cells perpetuates macrophage-mediated IL-1β release, resulting in the pathological accumulation of transitional epithelial cells and fibrotic remodeling. This application aims to (1) define the mechanisms sustaining persistent T-cell activation, (2) determine how dysregulated immune responses influence epithelial cell fate, and (3) elucidate the impact of over-reactive antiviral immunity on respiratory sequelae. We will leverage both murine post-viral models and patient samples to dissect the immunological and cellular pathways underlying chronic tissue damage. By pinpointing key drivers of persistent lung injury, our findings will guide the development of targeted therapeutic strategies to mitigate PASC-related fibrosis and improve patient outcomes.", "keywords": [ "2019-nCoV", "Acute", "Acute Disease", "Address", "Animal Model", "CD8-Positive T-Lymphocytes", "CD8B1 gene", "COVID-19 pandemic", "COVID-19 sequelae", "Cells", "Chronic", "Clinical", "Comparative Study", "Complex", "Development", "Dyspnea", "Epithelial Cells", "Epithelium", "Fibrosis", "Functional disorder", "Human", "Immune", "Immune response", "Immunologics", "Impairment", "Individual", "Infection", "Influenza", "Interleukin-1 beta", "Investigation", "Knowledge", "Long COVID", "Lung", "Lung Diseases", "Lung Transplantation", "Macrophage", "Maintenance", "Mediating", "Middle East Respiratory Syndrome Coronavirus", "Modeling", "Molecular", "Morbidity", "Mus", "Nature", "Oxygen", "Pathologic", "Pathway interactions", "Patient-Focused Outcomes", "Patients", "Persons", "Phase", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Predisposition", "Primary Infection", "Pulmonary Fibrosis", "Pulmonary Pathology", "Radiology Specialty", "Research", "Resolution", "Respiratory System", "Role", "SARS coronavirus", "Sampling", "Signal Transduction", "Supplementation", "Survivors", "Symptoms", "T memory cell", "T-Cell Activation", "Time", "Tissues", "Transitional Cell", "Transitional Epithelium", "Tropism", "Viral", "Viral Pneumonia", "Viral Respiratory Tract Infection", "Virus", "Virus Activation", "Virus Diseases", "acute COVID-19", "acute infection", "age related", "antiviral immunity", "autoreactivity", "chronic disease model", "clinically relevant", "cohort", "effective therapy", "epithelial stem cell", "experience", "idiopathic pulmonary fibrosis", "immune activation", "improved", "lung injury", "mouse model", "pulmonary", "pulmonary function", "respiratory", "response", "targeted treatment", "therapeutic target", "therapeutic vaccine", "treatment strategy" ], "approved": true } }, { "type": "Grant", "id": "16060", "attributes": { "award_id": "1R01AI203400-01", "title": "JAK-STAT inhibition to reduce inflammation during ART-treated SIV infection", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 44530, "first_name": "ROGER", "last_name": "PTAK", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-08-20", "end_date": "2031-07-31", "award_amount": 1418462, "principal_investigator": { "id": 44531, "first_name": "Nina R.", "last_name": "Derby", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 44532, "first_name": "Donald L", "last_name": "Sodora", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 3474, "ror": "", "name": "SEATTLE CHILDREN'S HOSPITAL", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "People with HIV (PWH) on antiretroviral therapy (ART) experience persistent immune activation and inflammation despite effective viral suppression. Over time, this results in chronic inflammatory conditions across multiple organ systems, including neurocognitive decline and liver disease. The high risk for these conditions in PWH necessitates the identification of therapies to suppress inflammation that would be an adjunct to ART. One promising approach is through inhibition of the JAK-STAT signaling pathway. Small molecule JAK inhibitors (JAKi) have been highly successful in treating chronic inflammatory diseases and a second-generation orally available JAKi, baricitinib, is FDA approved for rheumatoid arthritis, alopecia areata, and systemic inflammation associated with COVID19. Recently, two Phase 2 clinical trials were initiated to evaluate the ability ofbaricitinib to control HIV replication and associated inflammation in PWH. like all clinical trials, these are limited in the types of samples that can be collected, resulting in a restriction to the mechanistic understanding of any viral or immune benefits that are observed. This proposal will bridge this gap by testing baricitinib in SN-infected macaques on ART (SIV +ARn, a system that is recognized as the gold standard for mechanistically evaluating HIV treatments. Our studies will test the hypothesis that JAK inhibition will reduce levels ofinflammatory biomarkers in tissues ofSN+ARTmacagues better than ART alone and that this benefit will be present even in a heightened inflammation model of/ow-dose lipopolysaccharide (LPS). We further hypothesize that reduced inflammation will result in lower SN levels and a smaller SN reservoir due to a reduction in activation and homeostatic proliferation of SN target cells. We will test the hypothesis in two specific aims, the first will assess peripheral tissues (blood and lymph nodes), while the second will assesses deep tissue sites within the macaques (CNS, lungs, liver and GI tract). Inflammatory mediators, immune cells and viral reservoirs will be assessed at each of these tissue sites. This proposal is timely as it investigates JAKi as potential anti-inflammatory and anti-viral therapy in the context of SIV +ART macaques, assessing key tissue sites that cannot be easily accessed during human clinical trials. In addition, baricitinib will be evaluated in the context of heightened inflammation associated with low-dose LPS exposure, with the potential to uncover strengths or weaknesses regarding JAK inhibition that might not be observed in a clinical trial. The long-term goal of the proposed studies is to obtain mechanistic insights into the effectiveness of JAK inhibition during SIV+ART. If proven efficacious, it is possible that baricitinib will be utilized as a therapy to suppress inflammation, reduce HIV replication, reduce HIV reservoir size, and increase life expectancy for PWH. We hope that the repurposing ofbaricitinib to address a persistent problem for PWH will represent a paradigm shift in the treatment of chronic HIV infection in the United States and globally.", "keywords": [ "2019-nCoV", "Address", "Alopecia Areata", "Anti-Inflammatory Agents", "Anti-viral Therapy", "Atopic Dermatitis", "Biological Markers", "Biological Response Modifiers", "Blood", "Body System", "Brain", "COVID-19", "COVID-19 treatment", "Cardiovascular Diseases", "Cells", "Central Nervous System", "Clinical Trials", "Disease", "Dose", "Effectiveness", "FDA approved", "Gastrointestinal tract structure", "Generations", "Goals", "HIV", "HIV cure", "HIV replication", "HIV reservoir", "HIV therapy", "HLA-DR Antigens", "Human", "Immune", "In Vitro", "Infection", "Inflammation", "Inflammation Mediators", "Inflammatory", "Interleukin-6", "Interruption", "JAK1 gene", "JAK2 gene", "Janus kinase", "Life Expectancy", "Lipopolysaccharides", "Liver", "Liver diseases", "Lung", "Lung Diseases", "Macaca", "Macrophage Activation", "Marketing", "Modeling", "Morbidity", "Neurocognitive Deficit", "Oral", "Organ", "Peripheral", "Phase II Clinical Trials", "Play", "Proliferating", "Research", "Research Personnel", "Rheumatoid Arthritis", "Role", "SARS-CoV-2 inhibitor", "SIV", "STAT protein", "Sampling", "Scientist", "Signal Pathway", "Site", "System", "T-Lymphocyte", "TNF gene", "Testing", "Time", "Tissues", "Ulcerative Colitis", "United States", "Viral", "Viral reservoir", "Virus", "Virus Latency", "antiretroviral therapy", "asymptomatic HIV infection", "chronic inflammatory disease", "cytokine", "drug development", "experience", "experimental study", "high risk", "humanized mouse", "immune activation", "inhibitor", "insight", "lymph nodes", "monocyte", "mortality", "mouse model", "neurocognitive disorder", "people living with HIV", "peripheral blood", "repurposing", "small molecule", "systemic inflammatory response", "viral rebound" ], "approved": true } } ], "meta": { "pagination": { "page": 6, "pages": 1442, "count": 14420 } } }